An AOP analysis of selective serotonin reuptake inhibitors (SSRIs) for fish

Pharmaceuticals and personal care products (PPCPs) are found in measureable quantities within the aquatic environment. Selective serotonin reuptake inhibitor (SSRI) antidepressants are one class of pharmaceutical compound that has received a lot of attention. Consistent with most PPCPs, the pharmaco...

Full description

Saved in:
Bibliographic Details
Published in:Comparative biochemistry and physiology. Toxicology & pharmacology 2017-07, Vol.197, p.19-31
Main Author: McDonald, M. Danielle
Format: Article
Language:English
Subjects:
5-HT
Adverse Outcome Pathway
Aggression - drug effects
Animals
Antidepressant
Aquatic
Behavior
Ecotoxicology - methods
Feeding Behavior - drug effects
Female
Fish
Fish Proteins - antagonists & inhibitors
Fish Proteins - metabolism
Fishes
Fluoxetine
Male
Mammals
Physiology
Read-Across Hypothesis
Reproduction - drug effects
Serotonin - metabolism
Serotonin Plasma Membrane Transport Proteins - metabolism
Serotonin Uptake Inhibitors - pharmacokinetics
Serotonin Uptake Inhibitors - toxicity
SERT
Sertraline
Stress, Physiological - drug effects
Transport
Vertebrates
Water Pollutants, Chemical - toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pharmaceuticals and personal care products (PPCPs) are found in measureable quantities within the aquatic environment. Selective serotonin reuptake inhibitor (SSRI) antidepressants are one class of pharmaceutical compound that has received a lot of attention. Consistent with most PPCPs, the pharmacokinetics and physiological impacts of SSRI treatment have been well-studied in small mammals and humans and this, combined with the evolutionary conservation of the serotonergic system across vertebrates, allows for the read-across of known SSRI effects in mammals to potential SSRI impacts on aquatic organisms. Using an Adverse Outcome Pathway (AOP) framework, this review examines the similarities and differences between the mammalian and teleost fish SSRI target, the serotonin transporter (SERT; SLC6A4), and the downstream impacts of elevated extracellular serotonin (5-HT; 5-hydroxytryptamine), the consequence of SERT inhibition, on organ systems and physiological processes within teleost fish. This review also intends to reveal potentially understudied endpoints for SSRI toxicity based on what is known to be controlled by 5-HT in fish.
ISSN:1532-0456
1878-1659
DOI:10.1016/j.cbpc.2017.03.007